Cite
Gene Therapy Versus Common Care for Eligible Individuals With Sickle Cell Disease in the United States: A Cost-Effectiveness Analysis.
MLA
Basu, Anirban, et al. “Gene Therapy Versus Common Care for Eligible Individuals With Sickle Cell Disease in the United States: A Cost-Effectiveness Analysis.” Annals of Internal Medicine, vol. 177, no. 2, Feb. 2024, pp. 155–64. EBSCOhost, https://doi.org/10.7326/M23-1520.
APA
Basu, A., Winn, A. N., Johnson, K. M., Jiao, B., Devine, B., Hankins, J. S., Arnold, S. D., Bender, M. A., & Ramsey, S. D. (2024). Gene Therapy Versus Common Care for Eligible Individuals With Sickle Cell Disease in the United States: A Cost-Effectiveness Analysis. Annals of Internal Medicine, 177(2), 155–164. https://doi.org/10.7326/M23-1520
Chicago
Basu, Anirban, Aaron N. Winn, Kate M. Johnson, Boshen Jiao, Beth Devine, Jane S. Hankins, Staci D. Arnold, M.A. Bender, and Scott D. Ramsey. 2024. “Gene Therapy Versus Common Care for Eligible Individuals With Sickle Cell Disease in the United States: A Cost-Effectiveness Analysis.” Annals of Internal Medicine 177 (2): 155–64. doi:10.7326/M23-1520.